Abstract:The aim of the study was to investigate the risk factors of preprocedural laboratory investigations and drug effects to the incidence of contrast-induced nephropathy (CIN) in patients with diabetes who underwent coronary angiography or percutaneous coronary intervention and to assess the short-term safety. We retrospectively studied a total of 568 patients with diabetes who underwent coronary angiography or percutaneous coronary intervention from January, 2013 to January, 2014 in our hospital and compared the baseline clinical characteristics, especially the laboratory investigations and preprocedural drugs of those 2 groups (with CIN group and without CIN group), and half year follow-up. Overall, 53 (9.33%) patients were developed into CIN according to the definition of an increase of 25% from the baseline of serum creatinine concentration, supposing that on the basis of an increase of 44.2 μmol/L, the incidence would be 0.88% (5/568). No significant differences were found between the 2 groups with respect to age, diabetes mellitus duration, operation type, contrast type and volume, left ventricular ejection fraction, and combined diseases including hypertension, myocardial infarction, Arrhythmia, etc. However, patients with CIN tended to be lighter in body weight (P = 0.027) and were more often female [odds ratio (OR) = 2.8, P < 0.01], and also had a higher prevalence with acute coronary syndrome (OR = 5.1, P < 0.01). On the contrary to most studies, the preprocedural serum creatinine in with CIN group in our study was lower than without CIN group (P < 0.001). As for the preprocedural drugs, statins seemed could decrease the incidence of CIN (OR = 0.34, P < 0.05), and the use of diuretics might increase the occurrence of CIN (OR = 2.62, P < 0.05). As regard to the follow-up results, the hospitalization days and expense of with CIN group were significantly longer and higher than the without CIN group, but no significance was found between rehospitalization rate in half year. Preprocedural preventions are essential because there is no effective treatment for CIN our findings could be considered in clinical practice. There are many risk factors for CIN; it is necessary to distinguish the high-risk patients so as to carry out corresponding protection actions.

Study on intensive Atorvastatin Calcium in preventing radiographic con-trast nephropathy after percutaneous coronary intervention and its relat-ed risk factors

The Effect and Underlying Mechanism of Statins in the Prevention of Post-Contrast Acute Kidney Injury: A Multicenter Retrospective Observational Study

Clinical Observation about Effection of Atorvastatin on Preventing Renal Function in Patients with Coronary Heart Disease and Diabetes Mellitus

Effects of different doses of atorvastatin on prevention of contrast-induced nephropathy after percutaneous coronary intervention in patients with elevated high-sensitivity C-reactive protein:a comparative study

Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients with ST segment elevation myocardial infarction undergoing percutaneous coronary intervention

Atorvastatin Decreased Low Density Lipoprotein Level and Improved Coronary Artery Lesion in Patients after Percutaneous Coronary Intervention

The Value of Cystatin C in renal Dysfunction Related to Percutaneous Coronary Intervention

Efficacy of atorvastatin on renal function in patients with contrast-induced nephropathy after percutaneous coronary intervention

A Meta analysis of short term high dose atorvastatin to prevent contrast induced nephropathy after coronary angiography

Efficacy and Safety of Serial Atorvastatin Load in Chinese Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the ISCAP (intensive Statin Therapy for Chinese Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention) Randomized Controlled Trial

A comparative study of simvastatin and atorvastatin on contrast induced nephropathy in patients with coronary heart disease and diabetes mellitus during perioperative period of PCI

The association between nutritional risk and contrast-induced acute kidney injury in patients undergoing coronary angiography: a cross-sectional study

Rosuvastatin Attenuated Contrast-Induced Nephropathy in Diabetes Patients with Renal Dysfunction.

Efficacy of Short-Term Statin Treatment for the Prevention of Contrast-Induced Acute Kidney Injury in Patients Undergoing Coronary Angiography/Percutaneous Coronary Intervention: A Meta-Analysis of 21 Randomized Controlled Trials

Preventive Efficacy of Rosuvastatin for Contrast-induced Acute Kidney Injury in T2DM Combined with Kidney Insufficiency Patients with Blood Pressure of Unsatisfactory Control during Percutaneous Coronary Intervention

Efficacy of High-dose Statins Pretreatment on PCI-related Inflammation and Myocardial Injury

High Dose Atorvastatin on Coronary Artery Stenosis and hs-CRP in Patients with Unstable Angina Pectoris

Relationship Between High Sensitivity C-Reactive Protein and Contrast Induced Nephropathy

Renal Impact of High-Loading-dose Statin Pre-Cardiac Catheterization in Patients with Chronic Kidney Disease and Long-Term Statin Use

Efficacy of Statin Pretreatment for the Prevention of Contrast-Induced Nephropathy: a Meta-Analysis of Randomised Controlled Trials

Drug Effects and Clinical Investigations for Contrast-Induced Nephropathy after Coronary Angiography or Percutaneous Coronary Intervention in Patients with Diabetes.